Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future

Chiang, Chun‐Ju; Wang, Yingwei; Lee, Wen‐Chung

doi:10.1016/j.jfma.2019.01.012

Cited by 123 publications

(106 citation statements)

References 7 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…The study cohort was identified by the Taiwan Cancer Registry Database (TCRD), which contains data of all patients with newly diagnosed malignant cancers since 1979. 15 16 Essential information such as date of diagnosis, grade, cancer site and histological results are documented in the TCRD. In this study, data after duplicate checks and quality controls in the period of 2007–2014 were extracted to identify the incident cancer cases.…”

Section: Methodsmentioning

confidence: 99%

Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017

et al. 2020

View full text Add to dashboard Cite

ObjectiveCancers result in significant economic burdens on patients, health sectors and society. Reliable burden estimates will help guide resource allocation. This study aimed to perform a nationwide cost analysis of the direct and indirect costs of the top ten most costly cancers, and acute coronary syndrome (ACS), as a comparison, in Taiwan.SettingA population-based cohort study.ParticipantsIn total, 545 221 patients with newly diagnosed cancer (lung cancer, female breast cancer, colorectal cancer, liver cancer, oral cancer, leukaemia, prostate cancer, non-Hodgkin's lymphoma, gastric cancer and oesophageal cancer) and 170 879 patients with ACS between 2007 and 2014 were identified.Primary and secondary outcome measuresDirect medical costs were calculated from claims recorded in the National Health Insurance Research Database . Indirect costs, comprising morbidity-associated and mortality-associated productivity losses, were estimated from public life expectancy, average wage and employment data. The costs incurred in the 3 years after diagnosis were assessed. As a comparison, the cost of ACS was also estimated using the same study frame. A cost driver analysis was conducted to identify factors impacting cancer costs.ResultsThe cancers with the highest mean direct medical costs and total costs were leukaemia (US$28 464) and oesophageal cancer (US$81 775), respectively. Indirect costs accounted for over 50% of the total economic burden of most cancers, except for prostate cancer and female breast cancer. The costs of ACS were lower than those of most cancers. From the cost driver analysis, older age at diagnosis significantly (p<0.05) decreased the total cost of cancer; in contrast, male, tumour metastasis, comorbidities and treatment in medical centres increased the costs.ConclusionsThis study demonstrates the comprehensive economic burden of the top 10 most costly cancers in Taiwan. These results are valuable for optimising healthcare resource allocation.

show abstract

Section: Methodsmentioning

confidence: 99%

Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The TCR has a coverage rate of 98.4% and accounts for 0.9% of death certiﬁcate only (DCO). The percentages of histological and morphological veriﬁcation (MV) among all cancer sites were 93.0% and 97.6% after excluding the liver [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

“…e Taiwan Cancer Registry (TCR) is a population-based national cancer registration system that was established by the Ministry of Health and Welfare in 1979. e TCR has a coverage rate of 98.4% and accounts for 0.9% of death certificate only (DCO). e percentages of histological and morphological verification (MV) among all cancer sites were 93.0% and 97.6% after excluding the liver [12].…”

Section: Sources and Datamentioning

confidence: 99%

Cancer Incidence Characteristic Evolution Based on the National Cancer Registry in Taiwan

Huang

Chen

2020

Journal of Oncology

View full text Add to dashboard Cite

Introduction. Taiwan has committed itself to cancer prevention. This study investigates the impact of cancer prevention on cancer incidence in Taiwan. Objective. This study describes the secular trends and present status of cancer incidence in Taiwan during the years of 1988 to 2016. Methods. Age-standardized incidence rates (ASRs), age-specific incidence, and sex ratios for all cancers were calculated using data from the Taiwan Cancer Registry System for the years 1988 to 2016. Results and Conclusions. ASRs of cancer for males increased from 150.93 per 105 individuals in 1988 to 330.03 per 105 individuals in 2016, and, for females, they increased from 124.18 per 105 individuals in 1988 to 269.5 per 105 individuals in 2016. We found that cancer incidence has begun at younger ages and that the rates of cancer incidence are increasing faster. This study shows that the incidence of cancer in males has decreased slightly in recent years, while the incidence of cancer in females has continued to increase. The continuous promotion of health literacy, lifestyle modification, HBV and HPV vaccination, and cancer early screening can improve the effectiveness of cancer prevention.

show abstract

“…From the 20 items of all newly diagnosed cancers information (short-form database), TCR added detailed diagnosis and treatment items (long-form database) in 2002 for cancer types as oral cavity and pharynx (except nasopharynx), colon and rectum, liver, lung, breast, and cervix. In 2007, the prostate cancer was also added in the long-form database [37,38].…”

Section: Study Design and Data Sourcesmentioning

confidence: 99%

Does radiotherapy increase the risk of colorectal cancer among prostate cancer patients? A large population-based study

Cheng

Chao

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objective: The survival of prostate cancer (PC) patients after radiotherapy (RT) has improved over time, but it raises the debate of increased risk of secondary colorectal cancer (SCRC). This study aimed to assess whether RT for PC treatment increases the risk of SCRC in comparison with radical prostatectomy (RP). Methods: A population-based cohort of PC patients treated only with RT or only with RP between January 2007 and December 2015 was identified from the Taiwan Cancer Registry. The incidence rate of SCRC development was estimated using Cox regression model. Results: In this study, total 8,797 PC patients treated with either RT (n = 3,219) or RP (n =5,578). Patients subjected to RT were elder (higher percentage of 70≧years, p < 0.0001) and more advanced clinically (stage III: 22.90% vs. 11.87%; stage IV: 22.15% vs. 13.80%, p < 0.0001), compared to those subjected to RP. More patients subjected to RT had a much higher percentage of autoimmune disease (22.34% vs. 18.75%, p < 0.0001) and osteoarthritis and allied disorders (16.31% vs. 12.98%, p < 0.0001). Besides, RT patients had a higher percentage of underlying Crohn's disease (0.25% vs. 0.05%, p = 0.0230). Although almost all selected factors were not statistically significant, they presented the positive risk of SCRC for those under RP compared with those among RT. Besides, for PC patients in clinical stage I and II, patients with RP may have borderline significantly protective effects of SCRC compared with those under RT (stage I, HR: 0.14; 95% C.I.:0.01-1.39; p = 0.0929; stage II, HR: 1.92; 95% C.I.:0.93-3.95; p = 0.0775). Kaplan-Meier curves for a 3-year-period, which demonstrated no statistical difference in the risk of SCRC free between PC patients undergoing RT and RP (p = 0.9766).

show abstract

Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future

Cited by 123 publications

References 7 publications

Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017

Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017

Cancer Incidence Characteristic Evolution Based on the National Cancer Registry in Taiwan

Does radiotherapy increase the risk of colorectal cancer among prostate cancer patients? A large population-based study

Contact Info

Product

Resources

About